Hepion Pharmaceuticals, Inc.
For the period ended Mar 31, 2025. Filed May 19, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 19, 2025
HEPA$0.11-13.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenues | $— | $— |
| Cost and expenses: | ||
| Research and development | 22,235 | 2,539,568 |
| General and administrative | 1,258,360 | 2,642,749 |
| Total operating expenses | 1,280,595 | 5,182,317 |
| Loss from operations | (1,280,595) | (5,182,317) |
| Other income (expense): | ||
| Interest expense, net | (24,811) | (4,349) |
| Change in fair value of contingent consideration and derivative financial instruments | (4,800,481) | 1,930,652 |
| Inducement expense | — | (2,567,044) |
| Loss before income taxes | (6,105,887) | (5,823,058) |
| Income tax benefit | — | 2,969,252 |
| Net loss | $(6,105,887) | $(2,853,806) |
| Weighted-average common shares outstanding: | ||
| Basic and diluted | 2,836,700 | 101,450 |
| Net loss per common share: (see Note 10) | ||
| Basic and diluted | $(2.15) | $(28.13) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.